Section Arrow
Quote
KNSA.NASDAQ
- Kiniksa Pharmaceuticals International plc
Quotes are at least 15-min delayed:2025/02/23 10:28 EST
Last
 20.01
+0.32 (+1.63%)
Day High 
20.09 
Prev. Close
19.69 
1-M High
20.9 
Volume 
404.10K 
Bid
18.05
Ask
20.3
Day Low
19.5 
Open
19.9 
1-M Low
18.12 
Market Cap 
1.42B 
Currency USD 
P/E 199.31 
%Yield -- 
10-SMA 19.67 
20-SMA 19.74 
50-SMA 19.86 
52-W High 28.15 
52-W Low 16.56 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.12/--
Enterprise Value
1.43B
Balance Sheet
Book Value Per Share
6.05
Cash Flow
Cash Flow Yield
0.01
Income Statement
Total Revenue
270.26M
Operating Revenue Per Share
3.45
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
UPCUniverse Pharmaceuticals Inc0.2003+0.0578+40.56%-- 
TLRYTilray Brands0.9452+0.0775+8.93%-- 
CGCCanopy Growth Corp1.615+0.005+0.31%-- 
TXMDTherapeuticsMD1.291+0.281+27.82%0.39PE
TEVATeva Pharmaceutical Industries Limited16.74-0.26-1.53%-- 
Quotes are at least 15-min delayed：2025/02/23 10:28 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.